研究显示,在一些DCIS病人中,Tamoxifen将乳腺癌的复发率削减近一半。 Tamoxifen cuts breast cancer recurrence by nearly half in some DCIS patients, study shows.

最近San Antonio乳腺癌专题讨论会的研究表明,tamoxifen可以大大减少当地“有良好风险的”肺癌(DCIS)患者的乳腺癌复发,这些患者选择在没有放射治疗的情况下进行乳房保护手术。 Recent research at the San Antonio Breast Cancer Symposium suggests that tamoxifen can significantly reduce the recurrence of breast cancer in patients with "good-risk" ductal carcinoma in situ (DCIS) who opt for breast-conserving surgery without radiotherapy. “良好风险”是指1级或2级、2.5厘米或更小的肿瘤,其外科手术间距明显为3毫米或以上。 "Good-risk" refers to tumors that are grade 1 or 2, 2.5 cm or smaller, and have clear surgical margins of 3 mm or more. 该研究表明，他莫昔芬治疗患者的 15 年复发率为 11.4%，而未接受他莫昔芬治疗的患者为 19%。 The study showed a 15-year recurrence rate of 11.4% for tamoxifen-treated patients compared to 19% for those not treated with tamoxifen. 另一项研究表明,积极监测可能是低风险DCIS的即时手术的安全替代方案,在两年内侵入性癌症的发病率也会出现类似的结果. Another study indicates that active monitoring could be a safe alternative to immediate surgery for low-risk DCIS, with similar outcomes for invasive cancer rates over two years. 然而,还需要进行更多的长期研究。 However, more long-term studies are needed.